Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Nov 27;5(11):e1540. doi: 10.1038/cddis.2014.504

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International Licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0

PMC Copyright notice

Combination of bortezomib and citreoviridin enhanced the UPR, protein ubiquitination, and cytoplasmic vacuolation. (a) Cells treated with or without 0.1 μM citreoviridin (Citreo) and 10 nM bortezomib (Btz) for 48 h were harvested for western blotting analysis. Protein expression levels or total ubiquitinated protein (Ub) signals were normalized to actin and DMSO (−/−) levels, and the phosphorylated form of eIF2α was further normalized to the total eIF2α level. (b) Cells were seeded onto poly-L-lysine-coated coverslips and then treated with the indicated drugs for 5 days. ER and nuclei were labeled with calnexin (green) and DAPI (blue), respectively. Bar represents 10 μm